On 20 November, the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.
At the WHO Global Forum for Public Procurement of Health Products, a powerful reminder was shared by WHO’s Director-General, Dr. Tedros Adhanom Ghebreyesus.
Today marks the launch of Global Biosimilars Week 2025, an international awareness campaign led by the International Generic and Biosimilar Medicines Association (IGBA). This year’s theme, “Biosimilars: A Wise Investment for Global Health,” highlights the growing importance of biosimilar medicines in improving access to treatment, enhancing healthcare sustainability, and promoting global health equity.
- IGBA at UNGA Side Events (September 2025)
- IGBA Welcomes the WHO Pandemic Agreement and Calls for Action on Key Elements (July 2025)
- IGBA Statement at the 66th Series of Meetings of the WIPO Assemblies (July 2025)
- Calling for health and access to health for all as a priority in the upcoming G7 Leaders’ Summit – An IGBA perspective (June 2025)
